Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review
Abstract Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete,...
Saved in:
Published in | Medical principles and practice Vol. 33; no. 2; pp. 102 - 111 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
S. Karger AG
01.04.2024
|
Subjects | |
Online Access | Get full text |
ISSN | 1011-7571 1423-0151 1423-0151 |
DOI | 10.1159/000535965 |
Cover
Abstract | Abstract
Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. Results: We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042–1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917–1.630). Conclusions: Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence.
Highlights of the StudySurvivorship of prostate cancer (PCa) is arguably the most essential consideration when planning prostatectomy as a definitive treatment for PCa.The usefulness of total prostate-specific antigen (PSA) as a determinant of survivorship of PCa is reported with ambivalence.The study demonstrated that the sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. |
---|---|
AbstractList | [...]there is an urgent need to ascertain the odds for treatment success (BCR and mortality) with RP [6, 7]. [...]our study aimed to evaluate the relationship between pre-operative tPSA and survivorship of PCa following RP. [...]studies were considered if one or more of the dependent variables were linked to pre-operative tPSA. [...]to be eligible for inclusion in the meta-analysis study, we had to report adjusted HR and their corresponding 95% confidence intervals derived from multivariate regression models. This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042-1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917-1.630). Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence. Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. Results: We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042–1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917–1.630). Conclusions: Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence. This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa).OBJECTIVEThis review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa).Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity.METHODSData sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity.We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042-1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917-1.630).RESULTSWe found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042-1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917-1.630).Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence.CONCLUSIONSBiochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence. Abstract Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer (PCa). Methods: Data sources for the review included MEDLINE, PubMed, Cochrane Library, CINAHL, Academic Search Complete, PsycINFO, and relevant reference lists. Databases were searched from inception to June 2022. The study took place between May 2022 and March 2023. We included studies that applied a quantitative approach to examine the interaction between pre-operative PSA and survivorship of PCa. Pre-operative PSA constituted the independent variable, whereas survivorship of PCa as measured by biochemical recurrence and mortality constitute the outcome variable. A risk of bias assessment was conducted with the aid of a mixed-method appraisal tool. We employed meta-analysis to quantify the association of pre-operative PSA with biochemical recurrence and mortality and computed I2 to assess the degree of heterogeneity. Results: We found a positive weak association between pre-operative PSA and biochemical recurrence (hazard ratio [HR] = 1.074; 95% CI = 1.042–1.106). With a median rise in PSA (≥2 ng/mL), the likelihood for biochemical recurrence increase by approximately 7.4%. There was statistically a significant association between PSA and mortality (HR = 1.222, CI = 0.917–1.630). Conclusions: Biochemical recurrence associates with pre-operative PSA in an inconsistent manner. The sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. There is need for a multifactorial model which employs a prudent combination of the most important and cost-effective biomarkers in predicting post-prostatectomy biochemical recurrence. Highlights of the StudySurvivorship of prostate cancer (PCa) is arguably the most essential consideration when planning prostatectomy as a definitive treatment for PCa.The usefulness of total prostate-specific antigen (PSA) as a determinant of survivorship of PCa is reported with ambivalence.The study demonstrated that the sole use of pre-operative PSA in estimating post-prostatectomy biochemical recurrence should be discouraged. |
Author | Emedoh, Andrew Emeka Okwor, Chika Juliet Nweke, Martin Okwor, Vitalis Chukwuemeka Meka, Ijeoma A. |
Author_xml | – sequence: 1 givenname: Chika Juliet surname: Okwor fullname: Okwor, Chika Juliet – sequence: 2 givenname: Vitalis Chukwuemeka surname: Okwor fullname: Okwor, Vitalis Chukwuemeka – sequence: 3 givenname: Ijeoma A. surname: Meka fullname: Meka, Ijeoma A. email: *Ijeoma A. Meka, ijeoma.meka@unn.edu.ng – sequence: 4 givenname: Andrew Emeka surname: Emedoh fullname: Emedoh, Andrew Emeka – sequence: 5 givenname: Martin surname: Nweke fullname: Nweke, Martin |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38142683$$D View this record in MEDLINE/PubMed |
BookMark | eNptkk1v1DAQhi1URD_gwB0hS1zgELDjOHF6QatV-ZCKuuqWs-V1JluXrB1sJ6v9K_21uNolFMTFY71-9M54Zk7RkXUWEHpJyXtKef2BEMIZr0v-BJ3QImcZoZwepTuhNKt4RY_RaQh3CROMkWfomImElYKdoPtZCE4bFY2zeAVxC2DxwkN21YNP6gj4xkXVJc2FqCJkyx60aY3GMxvNOtHKNng5-NGMzodb02PXTjSeK6vB49Z1ndsau8bXqjH6kZ-ObrM7xzO83IUIm5RS42sYDWyfo6et6gK8OMQz9P3Txc38S3Z59fnrfHaZ6UKQmFHWtLlgDSUESk7qoqhywYGvdMmLBtKpGCVtpfOW1aysabHiiuRJqHgBpGVn6OPetx9WG2g02OhVJ3tvNsrvpFNG_v1iza1cu1FSSuqyqvPk8Pbg4N3PAUKUGxM0dJ2y4IYg85rwSlAmyoS--Qe9c4O36X-SkaLkORVcJOr145KmWn7PLQHv9oBObQwe2gmhRD7shJx24k_KH8qvwU_kt8ViT8i-eejCq_9SB5NfYFi_oQ |
ContentType | Journal Article |
Copyright | 2023 The Author(s). Published by S. Karger AG, Basel 2023 The Author(s). Published by S. Karger AG, Basel. 2023 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content 2023 The Author(s). Published by S. Karger AG, Basel 2023 |
Copyright_xml | – notice: 2023 The Author(s). Published by S. Karger AG, Basel – notice: 2023 The Author(s). Published by S. Karger AG, Basel. – notice: 2023 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content – notice: 2023 The Author(s). Published by S. Karger AG, Basel 2023 |
DBID | M-- AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
DOI | 10.1159/000535965 |
DatabaseName | Karger Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | TPSA Levels and Survival after Prostatectomy |
EISSN | 1423-0151 |
EndPage | 111 |
ExternalDocumentID | PMC11096792 38142683 10_1159_000535965 535965 |
Genre | Meta-Analysis Systematic Review Journal Article |
GroupedDBID | --- 0R~ 0~B 30W 326 36B 3O. 3V. 4.4 53G 5GY 7X7 88E 8FI 8FJ 8UI AAWTL AAYIC ABPAZ ABUWG ACGFS ADBBV AENEX AEYAO AFKRA AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CS3 CYUIP DU5 E0A E3Z EBS EMB EMOBN F5P FB. FYUFA GROUPED_DOAJ HMCUK HYE HZ~ IAO IHR KUZGX M-- M1P MK0 O1H O9- OK1 P2P PQQKQ PROAC PSQYO RKO RNS RPM SV3 UJ6 UKHRP AAYXX ABBTS ABWCG ACQXL ADAGL AFJJK AFSIO AHFRZ AIOBO CAG CITATION COF DIK EJD ITC PHGZM PHGZT PJZUB PPXIY RIG RXVBD TR2 CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c480t-13df283d100e6509447285e5bc654dec65a310f7c2f3936914b5a02f7c754e0f3 |
IEDL.DBID | 7X7 |
ISSN | 1011-7571 1423-0151 |
IngestDate | Thu Aug 21 18:35:35 EDT 2025 Fri Sep 05 11:16:26 EDT 2025 Fri Jul 25 04:10:44 EDT 2025 Sun May 18 01:30:14 EDT 2025 Tue Aug 05 12:09:27 EDT 2025 Thu Aug 29 12:04:27 EDT 2024 Sat Aug 31 21:00:32 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Prostatectomy Prognosis Prostate-specific antigen Survival |
Language | English |
License | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. https://creativecommons.org/licenses/by-nc/4.0 2023 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c480t-13df283d100e6509447285e5bc654dec65a310f7c2f3936914b5a02f7c754e0f3 |
Notes | ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
OpenAccessLink | https://karger.com/doi/10.1159/000535965 |
PMID | 38142683 |
PQID | 3046521858 |
PQPubID | 2047984 |
PageCount | 10 |
ParticipantIDs | crossref_primary_10_1159_000535965 proquest_journals_3046521858 proquest_miscellaneous_2905781386 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11096792 pubmed_primary_38142683 karger_primary_535965 |
PublicationCentury | 2000 |
PublicationDate | 2024-04-01 |
PublicationDateYYYYMMDD | 2024-04-01 |
PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Basel, Switzerland |
PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel |
PublicationTitle | Medical principles and practice |
PublicationTitleAlternate | Med Princ Pract |
PublicationYear | 2024 |
Publisher | S. Karger AG |
Publisher_xml | – name: S. Karger AG |
References | Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, . An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111(1):22–9. Erratum in: BJU Int. 2013;111(3):524. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJJr, DotanZA, DiBlasio CJ, . Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23(28):7005–12. Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, . Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States. Infect Agent Cancer. 2009;S2(Suppl 1):4. Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2023. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Sorce G, Hoeh B, . Contemporary pathological stage distribution after radical prostatectomy in North American high-risk prostate cancer patients. Clin Genitourin Cancer. 2022;20(5):e380–9. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, . Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9. Nwagha T, Nweke M. Stratification of risk factors of lung cancer-associated venous thromboembolism and determining the critical point for preemptive intervention: a systematic review with meta-analysis. Clin Med Insights Oncol. 2023;17:11795549231175221. Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, . Biochemical recurrence after radical prostatectomy: what does it mean. Int Braz J Urol. 2018;44(1):14–21. Lenhard W, Lenhard A. Calculation of effect sizes. Bibergau (Germany): Psyhometrica; 2015. http://www.psychometrica.de/effect_size.htlm. Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, . Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905–15. Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5(1):7–13. Vickers AJ, Eastham JA, Scardino PT, Lilja H. The memorial sloan kettering cancer center recommendations for prostate cancer screening. Urology. 2016;91:12–8. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, . Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. Prostate. 2022;82(6):687–94. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74. Würnschimmel C, Pose RM, Wenzel M, Tian Z, Incesu RB, Karakiewicz P, . Validation of the STAR-CAP clinical prognostic system for predicting biochemical recurrence, metastasis, and cancer-specific mortality after radical prostatectomy in a European cohort. Eur Urol. 2021;80(4):400–4. McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, . Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int. 2012;109(12):1764–9. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, , editors. Cochrane Handbook for systematic reviews of interventions version 6.3. Cochrane; 2022. Available from: www.training.cochrane.org/handbook (updated February 2022). D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294(4):440–7. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. Prostate. 2023;83(7):695–700. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of the type and number of d’amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. Cent Eur J Urol. 2023;76(2):104–8. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. Morgan SC, Morton GC, Berlin A, Cheung P, Chung P, Ménard C, . Current topics in radiotherapy for genitourinary cancers: consensus statements of the Genitourinary Radiation Oncologists of Canada. Can Urol Assoc J. 2020;14(11):E588–93. Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl. 2018;20(6):551–4. Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, . The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. Radiother Oncol. 2013;109(2):204–10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, . Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015;22(4):362–6. Morka N, Simpson BS, Ball R, Freeman A, Kirkham A, Kelly D, . Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy. BMJ Open. 2021;11(5):e047664. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039–46. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’Amico risk classification of prostate cancer. Adult Urol. 2007;70(5):931–5. Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, . The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels. Prostate. 2015;75(10):1034–42. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cut point for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61(2):365–9. Ikuemonisan J, Lediju O, Togun A, Adejoro O. Association between preoperative prostate-specific antigen levels and mortality in high- and intermediate-grade prostate cancer patients who received radical prostatectomy: findings from the SEER database. Prostate Int. 2021;9(2):72–7. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester, UK: John Wiley & Sons. Ltd; 2009. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49. Ferraro S, Biganzoli EM. The clinical value of assessing the intermethod bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med. 2021;60(2):149–51. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, . Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: globocan 2008. Int J Cancer. 2010;127(12):2893–917. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, . Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a pre-operative serum prostate-specific antigen level > or = 50 ng/mL. Cancer. 2008;113(7):1544–51. Nweke M, Ukwuoma M, Adiuku-Brown AC, Ugwu P, Nseka E. Characterization and stratification of the correlates of postpartum depression in sub-Saharan Africa: a systematic review with meta-analysis. Womens Health. 2022;18:17455057221118773. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, . The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Education Inf. 2018;34(4):285–91. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, . Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37(9):1618–25. |
References_xml | – reference: Vickers AJ, Eastham JA, Scardino PT, Lilja H. The memorial sloan kettering cancer center recommendations for prostate cancer screening. Urology. 2016;91:12–8. – reference: Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, . Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905–15. – reference: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. – reference: D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294(4):440–7. – reference: Ferraro S, Biganzoli EM. The clinical value of assessing the intermethod bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med. 2021;60(2):149–51. – reference: Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039–46. – reference: Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. Prostate. 2023;83(7):695–700. – reference: Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester, UK: John Wiley & Sons. Ltd; 2009. – reference: Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. – reference: Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, . Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31. – reference: Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, . Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015;22(4):362–6. – reference: Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2023. – reference: Ikuemonisan J, Lediju O, Togun A, Adejoro O. Association between preoperative prostate-specific antigen levels and mortality in high- and intermediate-grade prostate cancer patients who received radical prostatectomy: findings from the SEER database. Prostate Int. 2021;9(2):72–7. – reference: Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, . Biochemical recurrence after radical prostatectomy: what does it mean. Int Braz J Urol. 2018;44(1):14–21. – reference: Lenhard W, Lenhard A. Calculation of effect sizes. Bibergau (Germany): Psyhometrica; 2015. http://www.psychometrica.de/effect_size.htlm. – reference: Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Sorce G, Hoeh B, . Contemporary pathological stage distribution after radical prostatectomy in North American high-risk prostate cancer patients. Clin Genitourin Cancer. 2022;20(5):e380–9. – reference: Morka N, Simpson BS, Ball R, Freeman A, Kirkham A, Kelly D, . Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy. BMJ Open. 2021;11(5):e047664. – reference: Stephenson AJ, Scardino PT, Eastham JA, Bianco FJJr, DotanZA, DiBlasio CJ, . Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23(28):7005–12. – reference: McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, . Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int. 2012;109(12):1764–9. – reference: Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, . Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9. – reference: Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, . Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37(9):1618–25. – reference: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, , editors. Cochrane Handbook for systematic reviews of interventions version 6.3. Cochrane; 2022. Available from: www.training.cochrane.org/handbook (updated February 2022). – reference: Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, . Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. Prostate. 2022;82(6):687–94. – reference: Nwagha T, Nweke M. Stratification of risk factors of lung cancer-associated venous thromboembolism and determining the critical point for preemptive intervention: a systematic review with meta-analysis. Clin Med Insights Oncol. 2023;17:11795549231175221. – reference: Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49. – reference: Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, . An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111(1):22–9. Erratum in: BJU Int. 2013;111(3):524. – reference: Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, . Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States. Infect Agent Cancer. 2009;S2(Suppl 1):4. – reference: Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, . The association of the type and number of d’amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. Cent Eur J Urol. 2023;76(2):104–8. – reference: Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, . The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. Radiother Oncol. 2013;109(2):204–10. – reference: Nweke M, Ukwuoma M, Adiuku-Brown AC, Ugwu P, Nseka E. Characterization and stratification of the correlates of postpartum depression in sub-Saharan Africa: a systematic review with meta-analysis. Womens Health. 2022;18:17455057221118773. – reference: Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian J Androl. 2018;20(6):551–4. – reference: Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’Amico risk classification of prostate cancer. Adult Urol. 2007;70(5):931–5. – reference: Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, . The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels. Prostate. 2015;75(10):1034–42. – reference: Würnschimmel C, Pose RM, Wenzel M, Tian Z, Incesu RB, Karakiewicz P, . Validation of the STAR-CAP clinical prognostic system for predicting biochemical recurrence, metastasis, and cancer-specific mortality after radical prostatectomy in a European cohort. Eur Urol. 2021;80(4):400–4. – reference: Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5(1):7–13. – reference: Morgan SC, Morton GC, Berlin A, Cheung P, Chung P, Ménard C, . Current topics in radiotherapy for genitourinary cancers: consensus statements of the Genitourinary Radiation Oncologists of Canada. Can Urol Assoc J. 2020;14(11):E588–93. – reference: Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, . The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Education Inf. 2018;34(4):285–91. – reference: Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cut point for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61(2):365–9. – reference: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: globocan 2008. Int J Cancer. 2010;127(12):2893–917. – reference: Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, . Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a pre-operative serum prostate-specific antigen level > or = 50 ng/mL. Cancer. 2008;113(7):1544–51. – reference: D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74. |
SSID | ssj0008330 |
Score | 2.3352385 |
SecondaryResourceType | review_article |
Snippet | Abstract
Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship... Objective: This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of... This review aimed to systematically quantify the association between pre-operative total prostate-specific antigen (tPSA) and survivorship of prostate cancer... [...]there is an urgent need to ascertain the odds for treatment success (BCR and mortality) with RP [6, 7]. [...]our study aimed to evaluate the relationship... |
SourceID | pubmedcentral proquest pubmed crossref karger |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 102 |
SubjectTerms | Antigens Data analysis Humans Male Medical prognosis Medical Subject Headings-MeSH Mortality Multivariate analysis Neoplasm Recurrence, Local Preoperative Period Prostate cancer Prostate-Specific Antigen - blood Prostatectomy Prostatic Neoplasms - blood Prostatic Neoplasms - mortality Prostatic Neoplasms - surgery Risk assessment Survivor Systematic Review |
SummonAdditionalLinks | – databaseName: Karger Open Access Journals dbid: M-- link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3fT9swED4xQBUvaPwYZGPIIF6tJbGduLxVaFWFVFYNkPoWxYmtoWlJVVoQ_wp_7c52alG0veThzpGV3Nn32Xf-DHAhshKBasUoU2VNudYpVcxy47EsVhiucqPtfsf4Jhvd8-upmHb7HfYszG9b_-yoUQO3AAbcb56HpJ-JD7CFATe3xXtjSsOcKxnzvANJQrGDpOMQWnt1B3oYnjAiSbYWhLZ9n_-CmO8rJd-EnuFH2O0wIxl4I-_Bhm72oTfusuIH8PrmH5Ou8IpM5pr-mGlP7E3uWgTZKGvdASLqbp03DxUZNAtLx0nKpia3S5w2nlpX10xaE1qTK-sZc2LQZdpnDHXkZ-myO6FFtWj_vFySAbkNvNDEJx0O4X74_e5qRLs7F2jFZWxvpq8NIo46iWPtyPV4nkqhhaoywWuNzxIBocmr1DB7F2DClSjjFAW54Do27BNsNm2jjwG_lzNTx2lZcVxz6VoapVWlLIF-jgtvFsH5ygjFzFNrFG5JIvpFMFoEh948oclKfvJOPp5MvKqY1QbVK2MW3aB8LGwSGNGKFDKCs6DG4WRzJGWj2-VjkfYRwMqEySyCI2_70MPKeyKQa14RGliq7nVN8_DLUXZbXtcs76ef__M5X2AnRbTkS4JOYHMxX-qviHYW6tQ5-l-Wkfry priority: 102 providerName: Karger AG |
Title | Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review |
URI | https://karger.com/doi/10.1159/000535965 https://www.ncbi.nlm.nih.gov/pubmed/38142683 https://www.proquest.com/docview/3046521858 https://www.proquest.com/docview/2905781386 https://pubmed.ncbi.nlm.nih.gov/PMC11096792 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagRagXVKCUpWVlEFerSWwnWS5oW1oV0JZVH9LeovglKkS83QeIv8Kv7fixZlshLpZiW7KTGXs-eybfIPSOly0AVUkJFa0iTOuCCOq48WiZCTBXldHuvmN0Vp5esc8TPokXbvMYVrnaE_1Grax0d-QHzoMHpqbm9YfpDXFZo5x3NabQeIg2c0AiLnVDNUkHLkAXNLAR5DmBYfPILAQW_CAQmwycTVmzR4--u_Dr2b_Q5v2gyTUrdLKNnkT4iIdB3k_RA909Q49H0UH-HP1Z-9w4xmDh8UyTr1MdOL7xpQW8DXXW_0tEfAJ6cy3xsFs4Zk7cdgpfLGEH-Wl9iDO2JvXGR05JZtiA9thfYPXweesdPamHXNgfv9_jIb5IFNE4-B920NXJ8eXRKYnpF4hkdeaS1CsD4EPlWaY9zx6ripprLmTJmdJQtoANTSULQ11awJwJ3mYFVFSc6czQF2ijs51-ieB9GTUqK1rJ4PilVW2EFlI4Lv0KzuC0h96uhNBMA8tG408nfNAkSfXQThBP6rKq379XPxqPQ1MzVQaaV8Js4vqcN3-1qYfepGZYWc5d0nbaLudNMQAsW-e0LntoN8g-jQA4B6CNm3h9RytSB8fafbelu_7m2bsdxWtZDYpX_5_XHtoqAD-FIKF9tLGYLfVrwD8L0fdK3kebh8dn43N4-vjpS9_fJUA5IuQWuVoKsA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VgqAXxKPQLQUMgqPVxI8ki4TQqlBtabes6FbaW5qHLaqqyXYfVP0r_Ah-IzNxErYV4tZLDraVxJqx5xvP-BuAdzpIEKhmkss0ybkyRvBUEjeeDLwUzVVoDZ13DA6D_rH6OtbjFfjd3IWhtMpmT6w26rzM6Ix8myJ4aGoiHX2aXHCqGkXR1aaEhlOLfXN1iS7b7OPeZ5TveyF2v4x2-ryuKsAzFXlUez23aFNz3_NMRR-nQhFpo9Ms0Co3-EwQ8tgwE1ZStTtfpTrxBDaEWhnPSnzvHbirKMSI6ycctw4eohnp2A98n-M0_ZrJCBHDtiNS6ZINW7J_984o3Xv6L3R7M0lzyertPoKHNVxlPadfj2HFFE_g_qAOyD-FX0viZXXOFxtODf82MY5TnI1KxPfYVlZ3l3hV8N6eZqxXzIkJlCVFzo4WuGP9LKuUalbadjTbIaWcMovaWl6ilWXfkyqw1I7I5uX51QfWY0ctJTVz8Y51OL4VwTyD1aIszAbgfJW0uSeSTKG7Z_LIpibNUuLuD9Hnlx142wghnjhWj7jyhnQ3biXVgXUnnnZI0751o30wHLqueJJb7G6EGdf7wSz-q70deNN240qm8ExSmHIxi0UXsXPkyyjowHMn-_YLiKsQStGPR9e0oh1ALOHXe4rTHxVbOFHKBmFXbP7_v17Dg_5ocBAf7B3uv4A1gdjNJShtwep8ujAvEXvN01eVwjM4ue0V9gfNjEGD |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwEB2VFlW8IC4FFgoYBI_RJnYuXqQKLW1XLWWXqNtKfUvj2BYIkYS9UPVX-CS-inHshG2FeOtLHmxrk82MfY4z4zMAb6I4R6JaMI-JXHqhUtQTzGjjsdgXCFeJVuZ7x3gSH5yGH8-iszX43Z6FMWmV7ZrYLNSyKsw38r6J4CHU8Ij3tUuLSPdG7-sfnqkgZSKtbTmN3JVZkDuN3Jg75HGkLi9wOzffOdxD27-ldLR_snvguYoDXhFy39RllxrxVga-rxppuTChPFKRKOIolAqvOdIhnRRUM1MJLwhFlPsUG5IoVL5m-Lu3YCNB1MeN4MaH_Ul63OECZ8xqIwSBhy8hcDpHyCf6VmZlYBBuBR1vfzPJ4LN_cd_rKZwrmDi6B3cdmSVD6333YU2VD2Bz7ML1D-HXivGJywgj6Ux5n2tlFcfJSYXsH9uq5mSTN61VkyRIhvhq0bdJXkoyXeJ69rNqEq5JpbvRZNe47Ixo9OXqAjGYHOdN2KkbUSyq75fvyJBMO8FqYqMhW3B6I6Z5BOtlVaongP83ZFr6NC9C3AwqybVQohBG2T9JOGc9eN0aIaut5kfW7JWiQdZZqgdb1jzdkLZ9-1r7OE1tV1ZLjd2tMTO3Wsyzv77dg1ddN85zE7zJS1Ut5xkdILPmAeNxDx5b23d3QNaFRMs8OL_iFd0AoyF-taf8-qXREjeCs3EyoE___1wvYRNnW_bpcHL0DO5QJHY2e2kb1hezpXqOxGwhXjiPJ3B-05PsD_j4TF4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+Pre-Operative+Total+Prostate-Specific+Antigen+and+Survivorship+of+Prostate+Cancer+following+Radical+Prostatectomy%3A+A+Systematic+Review&rft.jtitle=Medical+principles+and+practice&rft.au=Okwor%2C+Chika+Juliet&rft.au=Okwor%2C+Vitalis+Chukwuemeka&rft.au=Meka%2C+Ijeoma+A&rft.au=Emedoh%2C+Andrew+Emeka&rft.date=2024-04-01&rft.issn=1423-0151&rft.eissn=1423-0151&rft.volume=33&rft.issue=2&rft.spage=102&rft_id=info:doi/10.1159%2F000535965&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-7571&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-7571&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-7571&client=summon |